Fundraising FoxKendall Capital Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Rejuvenate Biorejuvenatebio.com𝕏Jun 2026 · $10M
Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer.
BiotechHealthtechLongevitySan Diego, US
Noah Davidsohn(CSO, Co-Founder)inDaniel Oliver(CEO, Co-Founder)inGeorge Church(Co-Founder and SAB)Deborah Ascheim(Chief Medical Officer)in
BoardDavid Zhu(Director)in
Co-investorsCompanion FundConnecticut InnovationsDigitalis VenturesGaingelsLifespan Vision VenturesVCapital+1 more
__Twitter.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.